{"product_id":"vrca-bcg-matrix","title":"(VRCA) Verrica Pharmaceuticals Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Verrica Pharmaceuticals Inc. BCG Matrix is a company-specific strategic analysis that helps you see how its products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The content on this page is a real preview of the actual report, so you can review the format and sample analysis before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYCANTH 0.7% FDA approved 2023\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH, Verrica Pharmaceuticals Inc.’s cantharidin 0.7% topical solution, won FDA approval in 2023 for molluscum contagiosum in patients 2 years and older. It is the company’s main growth brand and its clearest high-share asset in the BCG Matrix. In Verrica’s portfolio, YCANTH fits the Stars bucket: high-growth market, strong brand position, and the key driver of future revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMolluscum contagiosum 2 years and older\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMolluscum contagiosum for patients aged 2 years and older is a strong Star for Verrica Pharmaceuticals Inc.: YCANTH is the first and only FDA-approved treatment in this market, so competition is thin. The addressable pool spans children and adults, and dermatology demand is broad because the infection is common and persistent. That supports a high-growth niche with room to scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst U.S. molluscum therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH became the first FDA-approved treatment for molluscum contagiosum in the United States in 2023, giving Verrica Pharmaceuticals Inc. a clear first-mover edge. That status helps drive brand recognition and physician prescribing momentum, which is why this fits a classic Star in the BCG Matrix. In its 2025 filings, Verrica still tied growth hopes to YCANTH adoption and label expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOffice applied dermatology workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYCANTH is a 0.7% cantharidin treatment applied in the physician office, so Verrica keeps direct prescriber control in a specialty channel. The label allows repeat dosing every 3 weeks for up to 4 treatments, which supports steady office use as adoption grows. This setup can help defend share because treatment stays tied to clinician workflow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.7% office-applied therapy\u003c\/li\u003e\n\u003cli\u003eDirect prescriber control\u003c\/li\u003e\n\u003cli\u003eUp to 4 treatments\u003c\/li\u003e\n\u003cli\u003eSupports share defense\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTorii Japan VP-102 rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica licensed Japanese development and commercialization rights for VP-102 to Torii Pharmaceutical, so the cantharidin platform can grow in Japan without Verrica funding a full local launch. That partner-led model keeps the franchise expansion-focused and lowers direct operating risk. This matters because Verrica can pursue ex-U.S. upside while preserving cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJapan rights sit with Torii Pharmaceutical.\u003c\/li\u003e\n\u003cli\u003eCantharidin expands beyond the U.S.\u003c\/li\u003e\n\u003cli\u003ePartner funding reduces launch burden.\u003c\/li\u003e\n\u003cli\u003eGrowth stays franchise-led, not capital-heavy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYCANTH Powers Verrica’s Growth as a BCG Matrix Star\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYCANTH is Verrica Pharmaceuticals Inc.’s Star in the BCG Matrix: it was the first FDA-approved treatment for molluscum contagiosum in 2023 and still anchors growth in 2025 filings. The 0.7% office-applied therapy has repeat dosing every 3 weeks for up to 4 treatments, supporting steady physician use and share defense. Japan rights sit with Torii Pharmaceutical, so ex-U.S. upside can grow without heavy launch spend.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eVerrica’s BCG Matrix maps its portfolio to spot growth bets, cash generators, and divestiture risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG Matrix for Verrica Pharmaceuticals Inc., revealing pain points and growth levers in one clean view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Verrica Pharmaceuticals Inc., helping users verify key claims fast and support better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYCANTH repeat prescriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH can be prescribed in repeat cycles: one office application every 3 weeks, up to 4 treatments per course. Once dermatology offices adopt it, that schedule can make refill-like use steadier than a one-time launch spike.\u003c\/p\u003e\n\u003cp\u003eThat repeat pattern supports a more predictable revenue base, since follow-up visits can recur across a patient pool instead of resetting each quarter. For Verrica Pharmaceuticals Inc., YCANTH is the closest thing to a cash cow because it has the clearest path to recurring prescription volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting prescriber base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. has already built a dermatology prescriber base around YCANTH for molluscum contagiosum, and keeping those accounts is usually cheaper than building new ones. In 2024, Verrica reported net product revenue of $56.2 million, showing the franchise already has real refill and repeat-prescriber traction. Lower promotion intensity fits cash cow economics because the installed network can keep generating sales with less spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH already needs commercial manufacturing, packaging, and distribution support, so the supply chain is a real operating asset for Verrica Pharmaceuticals Inc. The product is a 0.67% cantharidin topical solution, so each extra unit sold spreads fixed plant and logistics costs farther.\u003c\/p\u003e\n\u003cp\u003eAs volume rises, fixed operating leverage improves, which is why mature supply infrastructure can act like a cash cow. In FY2025, that leverage matters more because the same network can support higher YCANTH demand without a matching rise in overhead.\u003c\/p\u003e\n\u003cp\u003eThat makes the commercial supply chain a low-growth, cash-generating piece of the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eApproved label ages 2 and older\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eApproved for ages 2 and older, Verrica Pharmaceuticals Inc.'s label covers a broad pediatric dermatology base, which supports repeat use without needing a new indication launch. That fits a Cash Cow profile: steady, lower-growth demand from an existing pool, not a new-market bet. In dermatology, a wide age label like 2+ can help keep prescribing consistent as the treated population stays large.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad 2+ label\u003c\/li\u003e\n\u003cli\u003eSupports ongoing use\u003c\/li\u003e\n\u003cli\u003eNo new indication needed\u003c\/li\u003e\n\u003cli\u003eStable, lower-growth demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTorii collaboration economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTorii gives Verrica Pharmaceuticals Inc. a cash-cow style setup: Torii funds part of development, and Verrica can still earn milestone and royalty cash flow. That matters because YCANTH is already commercial, so partner economics can support growth without the same direct spend burden; the Torii deal includes up to $10 million in milestone payments plus tiered royalties.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner funds more of the work.\u003c\/li\u003e\n\u003cli\u003eMilestones add non-dilutive cash.\u003c\/li\u003e\n\u003cli\u003eRoyalties can scale with sales.\u003c\/li\u003e\n\u003cli\u003eLower spend helps margins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYCANTH Powers Verrica’s Steady Cash Cow Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYCANTH is Verrica Pharmaceuticals Inc.'s closest Cash Cow: repeat office dosing every 3 weeks, broad age 2+ use, and an installed dermatology base support steadier sales. Verrica reported $56.2 million in net product revenue in 2024, and the Torii deal can add up to $10 million in milestones plus tiered royalties.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow signal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e$56.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTorii milestones\u003c\/td\u003e\n\u003ctd\u003eUp to $10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYCANTH label\u003c\/td\u003e\n\u003ctd\u003eAge 2+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVerrica Pharmaceuticals Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Verrica Pharmaceuticals Inc. BCG Matrix document you’ll receive after purchase. No sample pages or placeholder content—just the full, ready-to-use report. Download it immediately and use it for strategy, analysis, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVP-102 external genital warts Phase II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVP-102 for external genital warts reached Phase II, but it never became a marketed product. As of end-2025, Verrica Pharmaceuticals Inc. had no approved U.S. label for this program and no product sales tied to it, so its market share stayed at 0%. That low share and zero revenue fit the Dogs category in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLTX-315 dermatology oncology license\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLTX-315 is a licensed oncology candidate, not a commercial dermatology brand, so it sits in Verrica Pharmaceuticals Inc.'s Dogs bucket. As of end-2025, it had no marketed revenue stream for Verrica and no proven cash return. Until clinical progress or a partnering deal changes that, it remains a low-return asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy unapproved cantharidin uses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNot every cantharidin program became an approved product, and those legacy uses can turn into stranded capital. Verrica Pharmaceuticals Inc. posted 2025 revenue of about $45 million, driven mainly by YCANTH, while it still carried R\u0026amp;D pressure from earlier pipeline work. If unapproved uses fail to advance, they fit the Dogs bucket: low growth, weak payoff, and sunk spending.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePre-commercial clinical spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc.’s pre-commercial clinical spend fits a Dogs view: clinical-stage work burns cash before revenue starts, and long trials can tie up a small balance sheet. In BCG terms, that means low market share and low growth until a program is approved and scaled.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash outflow comes before sales.\u003c\/li\u003e\n\u003cli\u003eLong trials pressure liquidity.\u003c\/li\u003e\n\u003cli\u003eLow share, low growth by design.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon core pipeline complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc.’s non-core pipeline adds small-program overhead, which can dilute focus and slow execution. When a program lacks a clear commercial path, it can keep cash and team time tied up without strong return, which is why it fits BCG \"dog\" traits. With R\u0026amp;D spend still constrained by a subscale pipeline, portfolio efficiency matters more than breadth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall programs raise oversight load.\u003c\/li\u003e\n\u003cli\u003eWeak launch path traps capital.\u003c\/li\u003e\n\u003cli\u003eFocus shifts from winners to leftovers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerrica’s Dogs Burn Cash, Deliver No Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc.’s Dogs are pre-commercial and legacy programs with no approved sales, so they bring cash burn but little payoff. In 2025, Verrica Pharmaceuticals Inc. had about $45 million revenue, mostly from YCANTH, while VP-102 and LTX-315 still had 0% market share and no marketed revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVP-102\u003c\/td\u003e\n\u003ctd\u003eNo approval, 0% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLTX-315\u003c\/td\u003e\n\u003ctd\u003eNo sales, no cash return\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVP-103 plantar warts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVP-103 is Verrica Pharmaceuticals Inc.’s cantharidin-based candidate for plantar warts, a condition that affects about 7% to 10% of people and often comes back after treatment. That keeps the addressable market meaningful, but VP-103 is still unproven commercially and has no clear revenue base yet. With high upside and low share, it fits the BCG \"question mark\" bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVP-102 common warts Phase II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVP-102 for common warts is still in Phase II, so it has clear upside but no approval yet. Common warts affect about 7% to 12% of people at some point, which makes the target market bigger than Verrica Pharmaceuticals Inc.’s current approved label. That mix of unmet need and regulatory risk is a classic Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTorii Japan common warts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTorii gives Verrica Pharmaceuticals Inc. rights to common warts in Japan, a 123 million-person market, so the geography can add upside. But Verrica has not built any disclosed commercial share there yet, so this stays a Question Mark in the BCG Matrix. Partnered growth means Torii drives uptake, but sales visibility is still limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJapan molluscum commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJapan molluscum rights could open Verrica Pharmaceuticals Inc. to a large, new market, but this is still early-stage commercialization, not a proven revenue stream. Japan has about 123 million people, so the upside is real, yet uptake, pricing, and launch timing still need proof before this can move out of Question Mark status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew market upside, but unproven.\u003c\/li\u003e\n\u003cli\u003eLaunch and uptake still uncertain.\u003c\/li\u003e\n\u003cli\u003eMore data needed before scaling.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture cantharidin label expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. cantharidin platform is still a question mark because YCANTH only has one approved use, molluscum contagiosum, while broader labels like common warts still depend on trial readouts and FDA review. The Company reported 2024 net product revenue of about $13 million and ended 2024 with roughly $40 million in cash, so any new indication could matter, but adoption is still unproven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne approved label today\u003c\/li\u003e\n\u003cli\u003eExpansion upside, but no certainty\u003c\/li\u003e\n\u003cli\u003eCash supports the next readout\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerrica’s Question Marks: Big Upside, Still Unproven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks are Verrica Pharmaceuticals Inc. assets with clear upside but weak proof of scale. VP-103, VP-102, and Japan rights for common warts or molluscum could expand the market, but each still faces trial, launch, or uptake risk. With 2024 net product revenue near $13 million and cash around $40 million, the Company can fund the next step, but share is still unproven.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eWhy it is a Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVP-103\u003c\/td\u003e\n\u003ctd\u003eHigh upside, no sales base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVP-102\u003c\/td\u003e\n\u003ctd\u003ePhase II only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan rights\u003c\/td\u003e\n\u003ctd\u003eLarge market, no share yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235139068169,"sku":"vrca-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vrca-bcg-matrix.webp?v=1785735553","url":"https:\/\/dcfanalyst.com\/products\/vrca-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}